Servier to acquire Edgewise’s muscular dystrophy unit in US$2.65B precision medicine deal

USA—Servier has entered into a definitive agreement to acquire Edgewise Therapeutics’ muscular dystrophy business for up to US$2.65 billion.

The deal includes an upfront payment of US$1.55 billion and additional regulatory and commercial milestone payments of up to US$1.1 billion.

The acquisition reinforces Servier’s growing commitment to rare neurology and reflects its broader ambition to expand treatment options for patients living with underserved and difficult-to-treat conditions.

Both companies have confirmed that their respective governance boards have approved the transaction, which now awaits regulatory clearance and completion of customary closing conditions.

The deal is expected to close in the third quarter of 2026.

Pipeline assets and scientific focus

Under the agreement, Servier will take control of Edgewise Therapeutics’ muscular dystrophy portfolio, including its lead candidate sevasemten.

The oral fast skeletal myosin inhibitor is currently undergoing pivotal clinical evaluation in patients with Becker muscular dystrophy and is also advancing through Phase II trials for Duchenne muscular dystrophy (DMD).

Sevasemten is designed to reduce contraction-induced muscle damage by targeting a key pathway implicated in the progression of certain rare neuromuscular disorders.

Its development represents a precision-based approach aimed at slowing disease progression and improving functional outcomes for affected individuals.

Becker muscular dystrophy is a genetic, X-linked condition that leads to gradual muscle degeneration over time and currently has no approved curative treatment.

Duchenne muscular dystrophy, a more severe recessive disorder, typically manifests in early childhood and results in progressive loss of mobility, with many patients experiencing significantly reduced life expectancy.

Leadership commentary and strategic direction

Servier president Olivier Laureau said the acquisition marks an important milestone in the company’s long-term neurology strategy, aligning with its Servier 2030 vision.

He noted that integrating Edgewise Therapeutics’ expertise and pipeline assets will help accelerate the development of targeted therapies for patients with rare neuromuscular diseases.

He added that the initiative reflects Servier’s mission to address conditions that currently have limited or no treatment options, particularly in both paediatric and adult populations affected by debilitating muscle disorders.

According to Laureau, the focus remains on advancing innovative therapies that can meaningfully improve patient outcomes in areas of high unmet medical need.

Integration and industry context

Following completion, Servier will integrate Edgewise’s muscular dystrophy operations into its broader rare disease and neurology portfolio, streamlining development efforts and strengthening its clinical pipeline.

The transaction also highlights ongoing consolidation within the rare disease and biotech sectors, where companies are increasingly pursuing targeted acquisitions to accelerate drug development.

Earlier in the year, Servier expanded its research footprint through a multi-year collaboration with Insilico Medicine valued at up to US$888m, aimed at advancing artificial intelligence-driven oncology drug discovery programs.

This partnership continues to reflect the company’s broader strategy of combining external innovation with internal development capabilities to build a diversified therapeutic pipeline.